STAAR Surgical Company Stock (NASDAQ:STAA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$26.14

52W Range

$25.89 - $52.68

50D Avg

$31.14

200D Avg

$37.58

Market Cap

$1.30B

Avg Vol (3M)

$737.47K

Beta

0.61

Div Yield

-

STAA Company Profile


STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,056

IPO Date

Feb 24, 1992

Website

STAA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Jan 21
Implantable Collamer Lenses$269.71M$212.91M$141.41M
Cataract Intraocular Lenses$9.64M$12.52M-
Other Surgical Products$5.04M$5.05M$8.48M
Intraocular Lenses--$13.57M

Fiscal year ends in Dec 23 | Currency in USD

STAA Financial Summary


Dec 23Dec 22Dec 21
Revenue$322.42K$284.39M$230.47M
Operating Income$28.10K$43.80M$33.34M
Net Income$21.35K$38.76M$24.50M
EBITDA$28.10K$50.02M$39.95M
Basic EPS$0.43$0.81$0.52
Diluted EPS$0.43$0.78$0.50

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 10:57 PM
Q2 24Aug 09, 24 | 11:49 AM
Q1 24May 07, 24 | 12:00 AM

Peer Comparison


TickerCompany
MMSIMerit Medical Systems, Inc.
COOThe Cooper Companies, Inc.
BDXBecton, Dickinson and Company
WSTWest Pharmaceutical Services, Inc.
RGENRepligen Corporation
HOLXHologic, Inc.
MBOTMicrobot Medical Inc.
RMDResMed Inc.
NVSTEnvista Holdings Corporation
ANGOAngioDynamics, Inc.
HAEHaemonetics Corporation
ICUIICU Medical, Inc.
ATRAptarGroup, Inc.